Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer
Abstract Triple-negative breast cancer (TNBC) is clinically defined by the absence of estrogen and progesterone receptors and the lack of membrane overexpression or gene amplification of receptor tyrosine kinase ErbB-2/HER2. Due to TNBC heterogeneity, clinical biomarkers and targeted therapies for t...
Main Authors: | Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-05-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-022-04855-0 |
Similar Items
-
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer
by: Santiago Madera, et al.
Published: (2023-12-01) -
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
by: Guangyuan Li, et al.
Published: (2014-01-01) -
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
by: Schillaci Roxana, et al.
Published: (2012-02-01) -
Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK.
by: Yong-Liang Yao, et al.
Published: (2013-01-01) -
Chromatin Modifications Sequentially Enhance ErbB2 Expression in ErbB2-Positive Breast Cancers
by: Sathish Kumar Mungamuri, et al.
Published: (2013-10-01)